Patents by Inventor Estelle Mottez

Estelle Mottez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
    Patent number: 6153408
    Abstract: An altered MHC class I determinant comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains encoded by a mammalian MHC class I locus in which the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 M domain. An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains encoded by a mammalian MHC class II locus, in which the domains are covalently linked to form a polypeptide comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 -.beta..sub.1 domains in sequence. The altered MHC class I and class II determinants can be associated with an antigen to elicit an immune response. The invention can be used in the immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock or snake bite.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: November 28, 2000
    Assignee: Institut Pasteur and Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean-Pierre Abastado, Estelle Mottez, Philippe Kourilsky, Armanda Casrouge, David Ojcius, Yu-Chun Lone
  • Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
    Patent number: 6011146
    Abstract: An altered MHC class I determinant comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains encoded by a mammalian MHC class I locus in which the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 M domain. An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains encoded by a mammalian MHC class II locus, in which the domains are covalently linked to form a polypeptide comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 -.beta..sub.1 domains in sequence. The altered MHC class I and class II determinants can be associated with an antigen to elicit an immune response. The invention can be used in the immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock or snake bite.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignees: Institut Pasteur, Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Estelle Mottez, Jean-Pierre Abastado, Philippe Kourilsky
  • Altered major histocompatibility complex (MHC) determinant and method of using the determinant
    Patent number: 5976551
    Abstract: An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, .beta..sub.2, domains of a mammalian MHC class II locus in which the domains are covalently linked to form a construct comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 .beta..sub.1 domains in sequence. The altered class II determinants can be associated with an antigen to elicit an immune response. In addition, the altered determinants may be used to prepare antibodies. The antibodies so produced have various diagnostic and therapeutic uses.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: Institut Pasteur and Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Estelle Mottez, Jean-Pierre Abastado, Philippe Kourilsky